Clinical Trial Update: Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency [Phase 4]

View source ↗

Summary

This Phase IV study evaluating the safety of ACZONE Gel 5% in people with acne vulgaris who have G6PD deficiency has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• ACZONE Gel 5% (Dapsone)

Snippet

Sponsor: Allergan | Conditions: Acne Vulgaris | Phase 4 | Status: COMPLETED